Format

Send to

Choose Destination
Nutr Metab Cardiovasc Dis. 2018 Jul;28(7):691-697. doi: 10.1016/j.numecd.2018.03.007. Epub 2018 Apr 10.

Soy isoflavones improve cardiovascular disease risk markers in women during the early menopause.

Author information

1
Academic Diabetes, Endocrinology and Metabolism, Hull York Medical School, University of Hull, Hull, UK.
2
Department of Academic Cardiology, University of Hull, UK.
3
European Food Safety Authority, Parma, Italy.
4
Weill Cornell Medical College Qatar, Education City, PO Box 24144, Doha, Qatar.
5
Department of Clinical Chemistry, Sidra Medical and Research Center, PO Box 26999, Doha, Qatar.
6
Weill Cornell Medical College Qatar, Education City, PO Box 24144, Doha, Qatar. Electronic address: sla2002@qatar-med.cornell.edu.

Abstract

BACKGROUND:

Hormone replacement therapy may be beneficial for cardiovascular disease risk (CVR) in post-menopausal women. Soy isoflavones may act as selective estrogen receptor modulators. The aim of this study was to evaluate whether soy isoflavones had an effect on CVR markers.

METHODS:

The expected 10-year risk of cardiovascular disease and mortality were calculated as a secondary endpoint from a double blind randomised parallel study involving 200 women (mean age 55 years, Caucasian, Hull, UK, 2012) in the early menopause who were randomised to 15 g soy protein with 66 mg isoflavone (SPI) or 15 g soy protein alone (depleted of all isoflavones; SP) given as a snack bar between meals daily for 6 months. Age, diabetes, smoking, blood pressure and lipid profiles were used to calculate CVR using the Framingham CVR engine.

RESULTS:

SPI treatment resulted in a significant reduction in the metabolic parameters and systolic blood pressure compared to SP (p < 0.01). There were no changes in fasting lipid profile and diastolic blood pressure with either treatment. At 6 months, changes in these parameters with SPI treatment were reflected in a calculated 27% (p < 0.01) reduction in 10 year coronary heart disease risk, a 37% (p < 0.01) reduction in myocardial infarction risk, a 24% (p < 0.04) reduction in cardiovascular disease and 42% (p < 0.02) reduction in cardiovascular disease death risk.

CONCLUSIONS:

Supplementation with soy protein with isoflavones for 6 months significantly improved CVR markers and calculated CVR at 6 months during early menopause compared to soy protein without isoflavones.

ISRCTN REGISTRY:

ISRCTN34051237.

KEYWORDS:

Cardiovascular death; Cardiovascular disease; Cardiovascular risk; Isoflavones; Postmenopausal; Soy; Stroke

PMID:
29739677
DOI:
10.1016/j.numecd.2018.03.007
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center